{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:43:24Z","timestamp":1793313804277,"version":"4.5.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"\n Importance<\/jats:title>\n Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an unmet need for treatments that provide rapid and high levels of skin clearance and itch improvement.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe AD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Heads Up was a 24-week, head-to-head, phase 3b, multicenter, randomized, double-blinded, double-dummy, active-controlled clinical trial comparing the safety and efficacy of upadacitinib with dupilumab among 673 adults with moderate-to-severe AD who were candidates for systemic therapy. The study was conducted from February 21, 2019, to December 9, 2020, at 129 centers located in 22 countries across Europe, North and South America, Oceania, and the Asia-Pacific region. Efficacy analyses were conducted in the intent-to-treat population.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized 1:1 and treated with oral upadacitinib, 30 mg once daily, or subcutaneous dupilumab, 300 mg every other week.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was achievement of 75% improvement in the Eczema Area and Severity Index (EASI75) at week 16. Secondary end points were percentage change from baseline in the Worst Pruritus Numerical Rating Scale (NRS) (weekly average), proportion of patients achieving EASI100 and EASI90 at week 16, percentage change from baseline in Worst Pruritus NRS at week 4, proportion of patients achieving EASI75 at week 2, percentage change from baseline in Worst Pruritus NRS (weekly average) at week 1, and Worst Pruritus NRS (weekly average) improvement of 4 points or more at week 16. End points at week 24 included EASI75, EASI90, EASI100, and improvement of 4 points or more in Worst Pruritus NRS from baseline (weekly average). Safety was assessed as treatment-emergent adverse events in all patients receiving 1 or more dose of either drug.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 924 patients screened, 342 (183 men [53.5%]; mean [SD] age, 36.2 [14.4] years) were randomized to receive upadacitinib and 331 were randomized to receive dupilumab (192 men [58.0%]; mean [SD] age, 36.3 [13.8] years); demographic and disease characteristics were balanced among treatment groups. At week 16, 248 patients receiving upadacitinib (72.4%) and 207 patients receiving dupilumab (62.6%) achieved EASI75 (\n P<\/jats:italic>\n \u2009=\u2009.007). All ranked secondary end points also demonstrated the superiority of upadacitinib vs dupilumab, including improvement in Worst Pruritus NRS as early as week 1 (mean [SE], 32.0% [1.8%] vs 8.9% [1.8%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), achievement of EASI75 as early as week 2 (152 [44.3%] vs 60 [18.2%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and achievement of EASI100 at week 16 (97 [28.4%] vs 26 [7.9%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Rates of serious infection, eczema herpeticum, herpes zoster, and laboratory-related adverse events were higher for patients who received upadacitinib, whereas rates of conjunctivitis and injection-site reactions were higher for patients who received dupilumab.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n During 16 weeks of treatment, upadacitinib demonstrated superior efficacy vs dupilumab in patients with moderate-to-severe AD, with no new safety signals.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03738397<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2021.3023","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T12:30:24Z","timestamp":1628080224000},"page":"1047","source":"Crossref","is-referenced-by-count":513,"title":["Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1001","volume":"157","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[{"name":"Oregon Medical Research Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique D.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy"},{"name":"Humanitas Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"De Bruin-Weller","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Barbarot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nantes Universit\u00e9, Centre Hospitalier Universitaire de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Division of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada"},{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada"},{"name":"Skin Health & Wellness Centre, Calgary, Alberta, Canada"},{"name":"Dermatology Research Institute, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lio","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Medical Dermatology Associates of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Hu","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshuang","family":"Wu","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Ladizinski","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina D.","family":"Chu","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi210044r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis.","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"10247","key":"doi210044r2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis.","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"doi210044r3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases.","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"doi210044r4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK inhibitors for atopic dermatitis: an update.","volume":"20","author":"He","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"doi210044r5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"doi210044r6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"issue":"3","key":"doi210044r7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"10290","key":"doi210044r8","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"issue":"10290","key":"doi210044r9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"20","key":"doi210044r10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"92","key":"doi210044r11","first-page":"44","article-title":"Diagnostic features of atopic dermatitis.","volume":"60","author":"Hanifin","year":"1980","journal-title":"Acta Dermatovener (Stockholm)"},{"key":"doi210044r12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.v184.5","article-title":"What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? a prospective observational study.","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi210044r13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/ddg.2008.6.issue-6","article-title":"Determinants of treatment goals and satisfaction of patients with atopic eczema.","volume":"6","author":"Schmitt","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"doi210044r14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40257-018-0381-6","article-title":"A comprehensive conceptual model of the experience of chronic itch in adults.","volume":"19","author":"Silverberg","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"doi210044r15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/jdv.v34.1","article-title":"Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation.","volume":"34","author":"Augustin","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi210044r16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches.","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"doi210044r17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial.","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"doi210044r18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"doi210044r19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.v183.2","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi210044r20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis, section 2: management and treatment of atopic dermatitis with topical therapies.","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2782803\/jamadermatology_blauvelt_2021_oi_210044_1721758666.55503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T11:07:40Z","timestamp":1721819260000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2782803"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}